Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer

NCT00107094 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00107094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00107094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2005
Completion date
Not reported
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer